GYRE
Price
$12.52
Change
+$1.38 (+12.39%)
Updated
Dec 23, 10:49 AM (EDT)
NAMS
Price
$25.51
Change
+$0.05 (+0.20%)
Updated
Dec 20, 04:59 PM (EDT)
95 days until earnings call
Ad is loading...

GYRE vs NAMS

Header iconGYRE vs NAMS Comparison
Open Charts GYRE vs NAMSBanner chart's image
Gyre Therapeutics
Price$12.52
Change+$1.38 (+12.39%)
Volume$200
CapitalizationN/A
NewAmsterdam Pharma
Price$25.51
Change+$0.05 (+0.20%)
Volume$21.13K
CapitalizationN/A
GYRE vs NAMS Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. NAMS commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and NAMS is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (GYRE: $11.14 vs. NAMS: $25.50)
Brand notoriety: GYRE and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 216% vs. NAMS: 115%
Market capitalization -- GYRE: $956.06M vs. NAMS: $2.73B
GYRE [@Biotechnology] is valued at $956.06M. NAMS’s [@Biotechnology] market capitalization is $2.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 5 TA indicator(s) are bullish while NAMS’s TA Score has 6 bullish TA indicator(s).

  • GYRE’s TA Score: 5 bullish, 5 bearish.
  • NAMS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а +15.56% price change this week, while NAMS (@Biotechnology) price change was +3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

GYRE is expected to report earnings on Nov 13, 2024.

NAMS is expected to report earnings on Mar 28, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.73B) has a higher market cap than GYRE($956M). NAMS YTD gains are higher at: 128.290 vs. GYRE (-56.637). GYRE has higher annual earnings (EBITDA): 11.8M vs. NAMS (-180.78M). NAMS has more cash in the bank: 423M vs. GYRE (25.1M). NAMS has less debt than GYRE: NAMS (506K) vs GYRE (1.8M). GYRE has higher revenues than NAMS: GYRE (105M) vs NAMS (33.6M).
GYRENAMSGYRE / NAMS
Capitalization956M2.73B35%
EBITDA11.8M-180.78M-7%
Gain YTD-56.637128.290-44%
P/E RatioN/AN/A-
Revenue105M33.6M313%
Total Cash25.1M423M6%
Total Debt1.8M506K355%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
68
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
5
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYRENAMS
RSI
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
56%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
38%
Momentum
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
47%
MACD
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
51%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
53%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
49%
Aroon
ODDS (%)
Bearish Trend 4 days ago
86%
N/A
View a ticker or compare two or three
Ad is loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMDCX2.960.05
+1.72%
Virtus Silvant Mid-Cap Growth C
HMVCX10.650.13
+1.24%
Hartford MidCap Value C
RAFCX40.760.40
+0.99%
American Funds AMCAP R3
TSRPX18.340.18
+0.99%
Nuveen Quant Small Cap Equity Premier
NRABX11.98-0.03
-0.23%
Neuberger Berman Abs Ret Multi-Mgr R6

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+4.50%
SPRC - GYRE
38%
Loosely correlated
-0.19%
HRMY - GYRE
38%
Loosely correlated
+1.15%
NAMS - GYRE
31%
Poorly correlated
+0.16%
ENGN - GYRE
30%
Poorly correlated
-2.18%
VRDN - GYRE
30%
Poorly correlated
+1.60%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with CMRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then CMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+0.16%
CMRX - NAMS
42%
Loosely correlated
+4.91%
QURE - NAMS
39%
Loosely correlated
+9.76%
GYRE - NAMS
32%
Poorly correlated
+4.50%
WXXWY - NAMS
24%
Poorly correlated
+2.22%
CRDF - NAMS
24%
Poorly correlated
-5.12%
More